Mednet Logo
HomeHospital Medicine
Hospital Medicine

Hospital Medicine

Physician discussions on inpatient care, transitions of care, diagnostic reasoning, and hospital-based protocols.

Recent Discussions

When and how should we use biomarkers (i.e., CRP, stool calprotectin, mAb levels) to guide or optimize medical management of Crohn’s disease or ulcerative colitis?

4
1 Answers

Mednet Member
Mednet Member
Gastroenterology · Icahn School of Medicine at Mount Sinai

The principal clinical applications of biomarkers in IBD are as follows: Assessment of severity and prognosis during a flareup. Monitoring the efficacy of treatment. Determining the probability of postoperative recurrence of Crohn’s disease (i.e., the high negative predictive value of FPC for anasto...

In patients with an acute gout flare who have stage 3–4 CKD or are on anticoagulation, what is your preferred first-line treatment?

3
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Kansas

This is a challenge. Intra-articular steroids may be the best option. Colchicine is an extremely complicated issue. A single dose of colchicine at 0.3 or 0.15 mg might be considered. Systemic steroids probably should be avoided because they reduce resistance to infection in an already compromised in...

Have you changed your approach to delaying hip surgery in the context of decompensated CHF given the findings of the HIP-ATTACK study?

1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Temple University Hospital

That is an interesting question. Patients with a hip fracture have a high mortality, and delaying surgery could contribute to this mortality. On the other side of the pendulum is acute heart failure. Patients with acute heart failure have increased mortality in the perioperative period. Some of this...

How do you balance the risks and benefits of stimulant treatment in patients with poorly controlled hypertension?

6
2 Answers

Mednet Member
Mednet Member
Psychiatry · University of Colorado

The short answer is that there are no clear cutoffs to clearly guide management, and often decisions are guided by shared decision making with patients and relevant specialties (psychiatry, primary care, cardiology).Clinical factors which may prompt you to stop or reduce stimulants: Elevated BP that...

What therapeutic approaches have you found effective for athletes with anorexia nervosa whose eating disorder symptoms are intertwined with sport-driven weight pressures?

1 Answers

Mednet Member
Mednet Member
Psychiatry · Oregon Health Sciences University

The gold standard for treatment of anorexia nervosa and all eating disorders is a team-based approach, including the individual, psychiatrist, counselor, primary care or sports medicine physician, dietician, appropriate family members, and, in the case of elite athletes, sometimes their coaches. Rap...

How should you manage a pediatric oncology patient who has an ANC > 500 and a normal chest x-ray but is confirmed to be infected with COVID-19 and is immunosuppressed from chemotherapy?

2
1 Answers

Mednet Member
Mednet Member
Pediatric Infectious Disease · St Jude Children's Research Hospital

The treatment for pediatric patients with cancer who develop COVID-19 is very poorly defined. The risk of severe disease is unknown because although adults with cancer appear to have worse outcomes than those without, non-immunocompromised children seem to have few severe outcomes from the disease a...

Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · UMass Memorial Medical Center

There are many functions of G-CSF, including repression of T-cell and NK cell function. Unless you are certain that growth factors are not modifying the immune network to the detriment of viral clearance—there is no data that growth factors help clear viral infections.

What are the current official guidelines regarding managing patients during COVID-19?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Yale School of Medicine

Here are some guidelines and FAQ from professional societies: NCCN: https://www.nccn.org/covid-19/default.aspx ASTRO FAQ: https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/COVID-19-FAQs ASCO Coronavirus Resources: https://www.asco.org/asco-coronavirus-information

What was the rationale for abrupt discontinuation of etanercept rather than gradual tapering in the SEAM-RA trial?

2 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama

The main goal of this trial was to get RA patients off of therapy and to see whether they would flare or maintain remission. We didn’t expect that the ultimate likelihood of success or failure was going to be primarily related to how long it took to do that. While a gradual withdrawal of the drug ma...

When do you use a carbapenem empirically to treat a patient with Acinetobacter infection?

2 Answers

Mednet Member
Mednet Member
Infectious Disease · Zucker School of Medicine at Hofstra / Northwell

Significant rates of Acinetobacter resistance to multiple classes of antimicrobial agents are a global concern. Mechanisms of resistance include bacterial production of beta-lactamases (i.e., carbapenemases), changes in porin channels, and alterations of target or cellular function due to mutations ...